These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 32877928

  • 1. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, Baloch Z, LiVolsi V, Krumeich L, Fraker DL, Nathanson KL, Cohen DL, Fishbein L.
    J Clin Endocrinol Metab; 2020 Dec 01; 105(12):e4661-70. PubMed ID: 32877928
    [Abstract] [Full Text] [Related]

  • 2. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
    Koh JM, Ahn SH, Kim H, Kim BJ, Sung TY, Kim YH, Hong SJ, Song DE, Lee SH.
    PLoS One; 2017 Dec 01; 12(11):e0187398. PubMed ID: 29117221
    [Abstract] [Full Text] [Related]

  • 3. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms.
    Stenman A, Zedenius J, Juhlin CC.
    Langenbecks Arch Surg; 2018 Sep 01; 403(6):785-790. PubMed ID: 29779047
    [Abstract] [Full Text] [Related]

  • 4. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
    Stenman A, Zedenius J, Juhlin CC.
    Surgery; 2019 Nov 01; 166(5):901-906. PubMed ID: 31239074
    [Abstract] [Full Text] [Related]

  • 5. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C, Agopiantz M, Brunaud L, Battaglia-Hsu SF, Max A, Pouget C, Nomine C, Lomazzi S, Vignaud JM, Weryha G, Oussalah A, Gauchotte G, Busby-Venner H.
    Virchows Arch; 2019 Jun 01; 474(6):721-734. PubMed ID: 30868297
    [Abstract] [Full Text] [Related]

  • 6. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T, Ito S, Kimura I, Naruse M, Phaeochromocytoma Study Group in Japan.
    Endocr Relat Cancer; 2014 Jun 01; 21(3):405-14. PubMed ID: 24521857
    [Abstract] [Full Text] [Related]

  • 7. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
    Kamai T, Murakami S, Arai K, Nishihara D, Uematsu T, Ishida K, Kijima T.
    BMC Cancer; 2022 Mar 18; 22(1):289. PubMed ID: 35300626
    [Abstract] [Full Text] [Related]

  • 8. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J, Martucci V, Wesley R, Fojo T, Del Rivero J, Huynh T, Adams K, Kebebew E, Frysak Z, Stratakis CA, Pacak K.
    BMC Cancer; 2014 Jul 21; 14():523. PubMed ID: 25048685
    [Abstract] [Full Text] [Related]

  • 9. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y, Sadowski SM, Alimchandani M, Quezado M, Steinberg SM, Nilubol N, Patel D, Prodanov T, Pacak K, Kebebew E.
    Surgery; 2017 Jan 21; 161(1):230-239. PubMed ID: 27839933
    [Abstract] [Full Text] [Related]

  • 10. Locally invasive recurrence or metastasis of pheochromocytoma into the liver?-clinicopathological challenges.
    Tang SS, Lee JWK, Wijerethne S, Iyer SG, Hue S, En NM, Parameswaran R.
    World J Surg Oncol; 2022 Nov 11; 20(1):360. PubMed ID: 36368995
    [Abstract] [Full Text] [Related]

  • 11. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
    De Filpo G, Cantini G, Rastrelli G, Vannini G, Ercolino T, Luconi M, Mannelli M, Maggi M, Canu L.
    J Endocrinol Invest; 2022 Jan 11; 45(1):149-157. PubMed ID: 34227051
    [Abstract] [Full Text] [Related]

  • 12. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
    Udager AM, Magers MJ, Goerke DM, Vinco ML, Siddiqui J, Cao X, Lucas DR, Myers JL, Chinnaiyan AM, McHugh JB, Giordano TJ, Else T, Mehra R.
    Hum Pathol; 2018 Jan 11; 71():47-54. PubMed ID: 29079178
    [Abstract] [Full Text] [Related]

  • 13. Pheochromocytomas and paragangliomas in humans and dogs.
    Galac S, Korpershoek E.
    Vet Comp Oncol; 2017 Dec 11; 15(4):1158-1170. PubMed ID: 28120550
    [Abstract] [Full Text] [Related]

  • 14. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
    Wang LL, Wei XJ, Zhang QC, Li F.
    Ann Diagn Pathol; 2022 Oct 11; 60():151981. PubMed ID: 35660808
    [Abstract] [Full Text] [Related]

  • 15. SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis.
    Su T, Yang Y, Jiang L, Xie J, Zhong X, Wu L, Jiang Y, Zhang C, Zhou W, Ye L, Ning G, Wang W.
    Front Endocrinol (Lausanne); 2023 Oct 11; 14():1121397. PubMed ID: 37008946
    [Abstract] [Full Text] [Related]

  • 16. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.
    Parasiliti-Caprino M, Lucatello B, Lopez C, Burrello J, Maletta F, Mistrangelo M, Migliore E, Tassone F, La Grotta A, Pia A, Reimondo G, Giordano R, Giraudo G, Piovesan A, Ciccone G, Deandreis D, Limone P, Orlandi F, Borretta G, Volante M, Mulatero P, Papotti M, Aimaretti G, Terzolo M, Morino M, Pasini B, Veglio F, Ghigo E, Arvat E, Maccario M.
    Hypertens Res; 2020 Jun 11; 43(6):500-510. PubMed ID: 31586159
    [Abstract] [Full Text] [Related]

  • 17. Paraganglioma: not just an extra-adrenal pheochromocytoma.
    Laird AM, Gauger PG, Doherty GM, Miller BS.
    Langenbecks Arch Surg; 2012 Feb 11; 397(2):247-53. PubMed ID: 22086065
    [Abstract] [Full Text] [Related]

  • 18. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
    Hamidi O, Young WF, Iñiguez-Ariza NM, Kittah NE, Gruber L, Bancos C, Tamhane S, Bancos I.
    J Clin Endocrinol Metab; 2017 Sep 01; 102(9):3296-3305. PubMed ID: 28605453
    [Abstract] [Full Text] [Related]

  • 19. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
    Yamazaki Y, Gao X, Pecori A, Nakamura Y, Tezuka Y, Omata K, Ono Y, Morimoto R, Satoh F, Sasano H.
    Front Endocrinol (Lausanne); 2020 Sep 01; 11():587769. PubMed ID: 33193100
    [Abstract] [Full Text] [Related]

  • 20. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C.
    J Clin Endocrinol Metab; 2011 Mar 01; 96(3):717-25. PubMed ID: 21190975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.